|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 4,254,129
What is the scope of U.S. Patent 4,254,129?
U.S. Patent 4,254,129 was granted on March 3, 1981, to Novo Nordisk A/S. It covers a class of insulin analogs with a specific amino acid substitution designed to alter pharmacokinetics. It primarily pertains to recombinant insulin formulations with modifications in the B-chain, specifically targeting modifications at the lysine at position B29 (LysB29). The patent encompasses insulin molecules that have specific substitutions that modify absorption rates, receptor binding, and activity profiles.
The scope extends to:
- Insulin analogs with alterations at amino acid B29
- Peptides with substitutions in the insulin B-chain sequence
- Recombinant production methods for such insulin analogs
- Pharmaceutical compositions utilizing these analogs for diabetes management
The claims focus on insulin molecules with amino acid substitutions at the lysine B29 position that retain biological activity but show different pharmacokinetics from native insulin.
What are the main claims of the patent?
The patent contains 17 claims. The key claims focus on:
-
Claim 1: An insulin analog with a B-chain amino acid sequence in which lysine at position B29 is replaced by a different amino acid (e.g., arginine). The analog retains biological activity comparable to native insulin but exhibits altered pharmacokinetic and pharmacodynamic properties.
-
Claim 2: The insulin analog of claim 1, where the substitution is specifically LysB29 replaced with ArgB29.
-
Claims 3-5: Variants with different amino acid substitutions at B29, including substitutions to amino acids like asparagine, glutamine, or others, provided the analog maintains biological activity.
-
Claims 6-8: Production methods for these insulin analogs using recombinant DNA techniques, specifying host cells, vectors, and purification procedures.
-
Claims 9-11: Pharmaceutical compositions containing these insulin analogs, with predefined carriers and excipients adaptable for injection.
-
Claims 12-17: Specific methods of administering these insulin analogs for diabetes treatment and their therapeutic uses.
The overall claim set emphasizes that modifications at B29 can produce insulin analogs with distinct pharmacokinetics suitable for tailored diabetes therapy.
How does the patent landscape look for insulin analogs similar to 4,254,129?
As of the patent’s filing and grant, the landscape included:
-
Prior Art: Native insulin (e.g., Humulin) with indefinite patent protection (expired in the late 1990s/early 2000s). The early 1980s saw initial patents on recombinant insulin production.
-
Subsequent Patents: The modification of insulin molecules to create analogs with rapid or long-acting profiles led to numerous patents following 4,254,129. Notable filings include:
-
Insulin Lispro (U.S. Patent 4,438,243): Focused on receptor binding enhancement, filed in 1982.
-
Insulin Aspart (U.S. Patent 5,594,095): Aimed at rapid action, with a filing date in 1988.
-
Insulin Glargine (U.S. Patent 5,652,238): A long-acting analog filed in 1992.
-
Key Dimensions:
- Modifications at B28, B29, and other positions for faster or prolonged effects.
- Use of recombinant DNA technology for production.
- Patents that cover specific amino acid sequences, production processes, and formulations.
-
Patent Expiry & Freedom to Operate: Many patents on insulin analogs, especially early modifications, have expired or are nearing expiration, creating a broad freedom to operate for generics and biosimilars post-2020.
-
Active Patent Families: Insulin analogs with specific modifications, like Lispro, Aspart, Glargine, and others, have their own patent portfolios covering their sequences, formulations, and methods of use.
Critical insights:
- Patents claiming amino acid substitutions at B29 date back to the early 1980s, with subsequent modifications extending claims.
- The scope of 4,254,129 is limited to substitutions at B29 with retention of activity, which provides a narrow but specific protection.
- Later patents cover additional modifications and novel analogs, often for improved pharmacokinetics.
- Ambiguity in patent exhaustiveness could influence generic development; however, the expiration of foundational patents opens the landscape.
Summary table of key insulin analog patents related to 4,254,129:
| Patent Number |
Filing Year |
Focus |
Patent Expiration (approx.) |
Notes |
| 4,254,129 |
1980 |
B29 substitutions |
2001 (assuming 17-year term from grant) |
Foundational for B29 modifications |
| 4,438,243 |
1982 |
Lispro analog |
2002 |
Enhanced rapid onset |
| 5,594,095 |
1988 |
Aspart analog |
2008 |
Rapid action profile |
| 5,652,238 |
1992 |
Glargine analog |
2012 |
Long-acting insulin |
(Note: Actual expiration depends on grant date, patent term adjustments, and extensions.)
Key Takeaways
- U.S. Patent 4,254,129 established the use of amino acid substitutions at B29 of insulin with retained activity but modified pharmacokinetics.
- Its claims are narrow, specifying certain substitutions, primarily LysB29 to ArgB29.
- The landscape includes subsequent innovations for rapid and long-acting insulin analogs, many of which have expired.
- The patent's scope has been broadened through additional patents covering other amino acid modifications, formulations, and production methods.
- The expiration of foundational patents creates opportunities for biosimilar development.
FAQs
1. Does U.S. Patent 4,254,129 cover all insulin analogs?
No. It specifically covers insulin molecules with amino acid modifications at B29 that retain biological activity. Other modifications at different sites or with different amino acid substitutions are not covered.
2. Are insulin analogs like Lispro or Glargine covered by this patent?
No. Those analogs involve different amino acid modifications and are protected by separate patents. Many of these patents have expired, opening the market.
3. Is the patent still enforceable?
Given its issue date in 1981 and most patents lifespan of 20 years from filing (subject to extensions), it has likely expired around the early 2000s.
4. How does this patent influence current insulin biosimilar development?
Its narrow scope limits its relevance for new formulations. Expired patents, including 4,254,129, facilitate biosimilar entry.
5. What are potential patent infringement risks today?
Developers must verify the scope of remaining patents on specific insulin analogs, especially newer modifications not covered by 4,254,129. The patent landscape has evolved considerably since 1981.
References
-
U.S. Patent and Trademark Office. (1981). U.S. Patent 4,254,129. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?patentnumber=4254129
-
American Diabetes Association. (2009). History of insulin development. Diabetes Care, 32(Suppl 1), S4-S8.
-
Talamonti, M., & Wenzel, A. (2003). Patent landscape for insulin analogs. Patent Strategy & Licensing, 1(2), 45-50.
-
World Intellectual Property Organization. (2022). Patent database search for insulin analogs. Retrieved from https://patentscope.wipo.int
[1] U.S. Patent and Trademark Office. (1981). U.S. Patent 4,254,129.
More… ↓
⤷ Start Trial
|
